#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14944	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2404	759.8	0	.	n	.	0	C1450T	SNP	1450	1450	C	1908	1908	T	950	T,C,G	862,86,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14944	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2404	759.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1642	1642	C	875	C,T	873,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25730	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4084	785.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1980	1980	A	1011	A,G,C	1009,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25730	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4084	785.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2614	2614	C	888	C	888	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25730	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4084	785.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2688	2688	A	880	A,G,C	876,2,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25730	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4084	785.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	3240	3240	C	885	C,G,A	883,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	527	2132	folP	855	855	100.0	folP.l15.c4.ctg.1	2016	130.4	1	SNP	p	R229S	1	.	.	685	687	AGC	1246	1248	AGC	213;214;215	A,G;G,T;C	212,1;213,1;215	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	527	2132	folP	855	197	91.88	folP.l15.c4.ctg.2	197	0.0	0	.	p	.	0	R136C	NONSYN	406	408	CGC	106	108	TGT	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	527	2132	folP	855	197	91.88	folP.l15.c4.ctg.2	197	0.0	0	.	p	.	0	R148Q	NONSYN	442	444	CGG	142	144	CAG	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	527	2132	folP	855	197	91.88	folP.l15.c4.ctg.2	197	0.0	0	.	p	.	0	T153N	NONSYN	457	459	ACC	157	159	AAC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	527	2132	folP	855	197	91.88	folP.l15.c4.ctg.2	197	0.0	0	.	p	.	0	D156I	NONSYN	466	468	GAC	166	168	ATT	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	527	2132	folP	855	368	93.32	folP.l15.c4.ctg.3	523	4.2	0	.	p	.	0	G195_F196insSG	INS	583	583	G	108	108	G	6	G	5	.	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	527	2132	folP	855	368	93.32	folP.l15.c4.ctg.3	523	4.2	0	.	p	.	0	M230T	NONSYN	688	690	ATG	219	221	ACG	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	527	2132	folP	855	368	93.32	folP.l15.c4.ctg.3	523	4.2	0	.	p	.	0	A238T	NONSYN	712	714	GCG	243	245	ACC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	527	2132	folP	855	368	93.32	folP.l15.c4.ctg.3	523	4.2	0	.	p	.	0	S254A	NONSYN	760	762	TCC	291	293	GCT	2;2;2	G;C;T	2;2;2	.	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	527	2132	folP	855	368	93.32	folP.l15.c4.ctg.3	523	4.2	1	SNP	p	R229S	1	.	.	685	687	AGC	216	218	AGC	ND;ND;ND	ND;ND;ND	ND;ND;ND	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5384	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3756	178.1	1	SNP	p	S91F	1	.	.	271	273	TTC	754	756	TTC	192;191;191	T,G,C;T,C;C	189,1,1;174,16;190	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5384	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3756	178.1	1	SNP	p	G95N	0	.	.	283	285	GGC	766	768	GGC	197;199;199	G,T,C;G,A,C;C,G	195,1,1;183,15,1;198,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5384	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3756	178.1	1	SNP	p	D95G	1	.	.	283	285	GGC	766	768	GGC	197;199;199	G,T,C;G,A,C;C,G	195,1,1;183,15,1;198,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	2006	mtrR	633	633	100.0	mtrR.l6.c4.ctg.1	1841	135.5	1	SNP	p	G45D	1	.	.	133	135	GAC	791	793	GAC	239;238;240	G;A;C,T,G	239;238;238,1,1	mtrR.WHO_K_01388:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	659	978	mtrR_promoter	250	250	99.2	mtrR_promoter.l15.c4.ctg.1	1456	83.4	0	.	n	.	0	G32A	SNP	32	32	G	605	605	A	209	A,G	185,24	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	659	978	mtrR_promoter	250	250	99.2	mtrR_promoter.l15.c4.ctg.1	1456	83.4	0	.	n	.	0	A197.	DEL	197	197	A	769	769	A	191	A	167	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	659	978	mtrR_promoter	250	250	99.2	mtrR_promoter.l15.c4.ctg.1	1456	83.4	0	HET	.	.	.	T193TAAAA,TAAAAA	.	193	193	T	766	766	T	191	TAAAA,TAAAAA	155,22	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	667	5070	parC	2304	2304	99.74	parC.l6.c30.ctg.1	3595	175.7	1	SNP	p	D86N	1	D86N	NONSYN	256	258	GAC	975	977	AAC	242;245;245	A,G;A;C,A	221,21;245;244,1	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	667	5070	parC	2304	2304	99.74	parC.l6.c30.ctg.1	3595	175.7	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1869	1871	ATC	233;232;233	A,G,C;T;C	209,23,1;232;233	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	667	5070	parC	2304	2304	99.74	parC.l6.c30.ctg.1	3595	175.7	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	2022	2024	GCA	244;241;242	G;C,T;A,G	243;218,23;218,23	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	667	5070	parC	2304	2304	99.74	parC.l6.c30.ctg.1	3595	175.7	1	SNP	p	S87R	0	.	.	259	261	AGT	978	980	AGT	240;238;237	A;G,T;T,A	240;237,1;236,1	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	667	5070	parC	2304	2304	99.74	parC.l6.c30.ctg.1	3595	175.7	1	SNP	p	S87W	0	.	.	259	261	AGT	978	980	AGT	240;238;237	A;G,T;T,A	240;237,1;236,1	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	667	5070	parC	2304	2304	99.74	parC.l6.c30.ctg.1	3595	175.7	1	SNP	p	S87I	0	.	.	259	261	AGT	978	980	AGT	240;238;237	A;G,T;T,A	240;237,1;236,1	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	667	5070	parC	2304	2304	99.74	parC.l6.c30.ctg.1	3595	175.7	1	SNP	p	S88P	0	.	.	262	264	TCC	981	983	TCC	237;235;239	T;C,A;C	237;234,1;239	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	667	5070	parC	2304	2304	99.74	parC.l6.c30.ctg.1	3595	175.7	0	HET	.	.	.	T312C	.	312	312	T	1031	1031	T	235	T,C	210,25	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4404	parE	1986	1986	99.9	parE.l15.c4.ctg.1	3132	175.1	0	.	p	.	0	V89A	NONSYN	265	267	GTC	844	846	GCC	220;220;222	G;C,T;C,T	220;197,23;221,1	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4404	parE	1986	1986	99.9	parE.l15.c4.ctg.1	3132	175.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1807	1809	GGC	248;248;249	G;G;C	248;248;249	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.002	penA.2.002	1	1	27	4090	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2851	178.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1432	1434	GCA	264;266;266	G,T;C;A,T	263,1;266;265,1	penA.2.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4090	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2851	178.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1435	1437	ATC	266;267;272	A;T,G;C,T	266;266,1;270,2	penA.2.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4090	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2851	178.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1447	1449	GTG	253;255;255	G;T,G;G,C	253;254,1;254,1	penA.2.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4090	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2851	178.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1447	1449	GTG	253;255;255	G;T,G;G,C	253;254,1;254,1	penA.2.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4090	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2851	178.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1951	1953	ACC	224;223;224	A,G;C;C,A	223,1;223;223,1	penA.2.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4090	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2851	178.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2005	2007	GCG	218;218;218	G;C;G	218;218;218	penA.2.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4090	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2851	178.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2005	2007	GCG	218;218;218	G;C;G	218;218;218	penA.2.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4090	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2851	178.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2128	2130	GGC	236;234;234	G;G,A,T;C,A	236;232,1,1;233,1	penA.2.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4090	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2851	178.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2137	2139	GGC	238;234;232	G,C;G;C	237,1;234;232	penA.2.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4090	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2851	178.6	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2155	2157	CCG	233;232;230	C,G;C,T;G,C	231,2;231,1;229,1	penA.2.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	667	5562	ponA	2397	2397	99.87	ponA.l15.c4.ctg.1	3656	189.5	0	.	p	.	0	A375T	NONSYN	1123	1125	GCG	1805	1807	ACG	225;227;226	A,G;C;G	208,17;227;226	.	.
porA.NCCP11945	porA.NCCP11945	1	0	659	3118	porA	1146	1146	99.74	porA.l15.c4.ctg.1	2278	170.3	0	.	p	.	0	S22G	NONSYN	64	66	AGC	576	578	GGC	215;216;215	G,A;G,A;C	166,49;215,1;215	.	.
porA.NCCP11945	porA.NCCP11945	1	0	659	3118	porA	1146	1146	99.74	porA.l15.c4.ctg.1	2278	170.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	758	758	C	232	C	232	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	314	porB1a	984	205	94.63	porB1a.l15.c17.ctg.2	208	43.6	0	.	p	.	0	V258L	NONSYN	772	774	GTA	59	61	TTA	30;34;36	T,G;T;A	28,2;34;36	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	314	porB1a	984	205	94.63	porB1a.l15.c17.ctg.2	208	43.6	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	104	106	CAT	72;72;72	C,G;A;T	62,10;72;72	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	314	porB1a	984	205	94.63	porB1a.l15.c17.ctg.2	208	43.6	0	.	p	.	0	D274S	NONSYN	820	822	GAT	107	109	AGT	72;72;72	A;G;T	72;72;72	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	314	porB1a	984	205	94.63	porB1a.l15.c17.ctg.2	208	43.6	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	116	118	TAC	72;72;72	T,C;A;C,A	62,10;72;71,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3046	porB1b	1047	1047	98.19	porB1b.l15.c30.ctg.1	1651	222.6	0	.	p	.	0	T26A	NONSYN	76	78	ACC	534	536	GCC	276;276;272	G,A;C;C,G	275,1;276;271,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3046	porB1b	1047	1047	98.19	porB1b.l15.c30.ctg.1	1651	222.6	0	.	p	.	0	N38E	NONSYN	112	114	AAT	570	572	GAA	254;255;257	G;A,T;A	254;254,1;257	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3046	porB1b	1047	1047	98.19	porB1b.l15.c30.ctg.1	1651	222.6	0	.	p	.	0	K41D	NONSYN	121	123	AAA	579	581	GAC	248;248;247	G;A;C,A	248;248;232,15	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3046	porB1b	1047	1047	98.19	porB1b.l15.c30.ctg.1	1651	222.6	0	.	p	.	0	N134D	NONSYN	400	402	AAT	858	860	GAT	253;255;255	G,A;A;T	236,17;255;255	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3046	porB1b	1047	1047	98.19	porB1b.l15.c30.ctg.1	1651	222.6	0	.	p	.	0	P175S	NONSYN	523	525	CCA	981	983	TCA	269;272;272	T;C;A,C	269;272;271,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3046	porB1b	1047	1047	98.19	porB1b.l15.c30.ctg.1	1651	222.6	0	.	p	.	0	A218I	NONSYN	652	654	GCC	1110	1112	ATC	266;265;265	A,C;T,C;C,G	265,1;264,1;240,25	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3046	porB1b	1047	1047	98.19	porB1b.l15.c30.ctg.1	1651	222.6	0	.	p	.	0	F222L	NONSYN	664	666	TTT	1122	1124	CTT	255;255;253	C,T;T;T,C	231,24;255;252,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3046	porB1b	1047	1047	98.19	porB1b.l15.c30.ctg.1	1651	222.6	0	.	p	.	0	T256G	NONSYN	766	768	ACA	1224	1226	GGA	224;222;222	G,C;G,C;A	223,1;210,12;222	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3046	porB1b	1047	1047	98.19	porB1b.l15.c30.ctg.1	1651	222.6	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1227	1229	ACG	222;221;219	A;C;G,T	222;221;218,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3046	porB1b	1047	1047	98.19	porB1b.l15.c30.ctg.1	1651	222.6	0	.	p	.	0	N260S	NONSYN	778	780	AAT	1236	1238	AGT	215;213;212	A,C;G,A;T	214,1;202,11;212	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3046	porB1b	1047	1047	98.19	porB1b.l15.c30.ctg.1	1651	222.6	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1440	1442	GCA	257;256;255	G,A;C,A;A,G	256,1;229,27;254,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3046	porB1b	1047	1047	98.19	porB1b.l15.c30.ctg.1	1651	222.6	1	SNP	p	G120K	1	.	.	358	360	AAG	816	818	AAG	230;236;248	A;A;G,A	230;232;243,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3046	porB1b	1047	1047	98.19	porB1b.l15.c30.ctg.1	1651	222.6	1	SNP	p	A121D	1	.	.	361	363	GAC	819	821	GAC	246;249;250	G,C;A;C	240,2;243;248	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3046	porB1b	1047	1047	98.19	porB1b.l15.c30.ctg.1	1651	222.6	1	SNP	p	D121N	0	.	.	361	363	GAC	819	821	GAC	246;249;250	G,C;A;C	240,2;243;248	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10274	rpoB	4179	4179	99.95	rpoB.l15.c4.ctg.1	5242	244.3	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2198	2200	AAT	282;278;277	A;A,G;T	282;276,2;277	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1382	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1621	106.2	1	SNP	p	V57M	1	.	.	169	171	ATG	854	856	ATG	221;222;221	A;T;G	221;222;221	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
